市場調查報告書

術後的噁心和嘔吐 (PONV) - 市場考察,流行病學,市場預測:2028年

Postoperative nausea and vomiting (PONV) - Market Insights, Epidemiology, and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 923105
出版日期 內容資訊 英文 159 Pages
商品交期: 最快1-2個工作天內
價格
術後的噁心和嘔吐 (PONV) - 市場考察,流行病學,市場預測:2028年 Postoperative nausea and vomiting (PONV) - Market Insights, Epidemiology, and Market Forecast - 2028
出版日期: 2019年12月01日內容資訊: 英文 159 Pages
簡介

主要7個國家 (美國,德國,西班牙,義大利,法國,英國,日本)的術後的噁心和嘔吐 (PONV) 市場在2017年估算為約18億9053萬美元。

本報告提供全球術後的噁心和嘔吐 (PONV) 治療藥市場相關調查分析,提供疾病的背景,流行病學,主要7個國家的市場趨勢相關的系統性資訊。

目錄

第1章 主要考察

第2章 PONV市場概要

  • 2017年的術後的噁心和嘔吐 (PONV)的市場佔有率 (%) 分佈
  • 2028年的術後的噁心和嘔吐 (PONV)的市場佔有率 (%) 分佈

第3章 術後的噁心和嘔吐 (PONV) :疾病的背景和概要

  • 簡介
  • 術後的噁心和嘔吐 (PONV)的病因與危險因素
  • PONV的原因
  • 術後的噁心和嘔吐 (PONV)的病理學的·神經化學的機制
  • 術後的噁心和嘔吐 (PONV)的遺傳的背景
  • 術後的噁心和嘔吐 (PONV)的預測的風險評分

第4章 病例報告

  • 病例報告:術後的噁心和嘔吐
  • 術後併發症

第5章 流行病學和患者族群

  • 主要調查結果
  • 流行病學與市場調查手法
  • 主要7個國家的住院患者整體手術數
  • 美國的流行病學
  • EU5個國家的流行病學
  • 日本的流行病學

第6章 術後的噁心和嘔吐 (PONV)的治療與管理

  • 止吐劑的首選
  • 二次止吐劑干預
  • 預防·治療策略
  • 治療流程
  • 治療指南

第7章 未滿足需求

第8章 上市藥

  • Aloxi (palonosetron hydrochloride) :Helsinn Healthcare
  • Zuplenz (ondansetron) :Midatech/Galena Biopharma
  • Emend (aprepitant) :Merck

第9章 新興藥

  • Barhemsys (APD421): Acacia Pharma
  • CR845 (difelikefalin): Cara Therapeutics
  • CAM2058: Camurus/Braeburn

第10章 術後的噁心和嘔吐 (PONV) :主要7個國家的市場分析

  • 主要調查結果
  • 主要7個國家的術後噁心和嘔吐 (PONV)的整體市場規模
  • PONV預防市場:現在·不同新興治療
  • PONV救命治療市場:現在·不同新興治療
  • 術後的噁心和嘔吐 (PONV)的市場規模:主要7個國家的不同治療

第11章 市場預測:主要7個國家

  • 美國的市場規模
  • EU5個國家
  • 日本

第12章 推動市場要素

第13章 市場障礙

第14章 SWOT分析

第15章 附錄

第16章 DelveInsight的功能

第17章 免責事項

第18章 關於DelveInsight

目錄
Product Code: DIMI0847

DelveInsight's 'Postoperative nausea and vomiting (PONV) - Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of PONV in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Postoperative nausea and vomiting (PONV) is an enormous problem for patients recovering after surgery. About one-third of people experience vomiting, and half of them experience nausea. Nausea, retching, or vomiting usually occurs during the first 24-48 h after surgery in inpatients. PONV is a common side effect following sedation and general anesthesia.

If these symptoms occur from 24 h following the discharge up to 72 h, it is called postdischarge nausea and vomiting (PDNV). In preoperative surveys, PONV is rated as the most likely to avoid anesthesia outcomes by the patients.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

PONV-Disease Understanding

Postoperative nausea and vomiting (PONV) can be one of the most distressing parts of the surgical journey. It affects approximately 20-30% of patients within the first 24-48 h postsurgery. Unresolved PONV may result in prolonged postanesthesia care unit (PACU) stay and unanticipated hospital admission that results in a significant increase in overall health care costs. The goal of PONV prophylaxis is, therefore, to decrease the cases of PONV and thus patient-related distress and reduce health care costs.

PONV Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Inpatient Surgical Cases in the 7MM, Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in the 7MM, Total Number of Patient showing Nausea and Vomiting in the 7MM and Total Number of Post-operative Nausea and Vomiting patients in the 7MM, scenario of PONV in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017-2028.

According to DelveInsight's, the total inpatients surgical cases in the 7 major markets was 52,032,174 in 2017. These cases are increases with a significant CAGR during study period (2017-2028). The total PONV cases in the 7 major markets was 16,980,822 in 2017.

PONV Drug Chapters

The treatment strategy includes single and combination of the antiemetic, which works on different receptor classes that result in additive effects. The major drug classes used for prophylaxis and treatment of PONV include histamine receptor antagonists, muscarinic receptor antagonists, dopamine receptor antagonists, serotonin type 3 (5-HT3) receptor antagonists, and tachykinin 1 (NK1) receptor, antagonists.

The three therapies which are approved in the US for the management of PONV after 2000 are Aloxi, Zuplenz, and Emend. In September 2019, the PONV indication was removed from the Emend capsule as per the US prescription information; however, it remains in the labeling for generic aprepitant capsules. Other PONV drugs, which are discontinued in the US are Kytril, Phenergan, and Compazine. The generic versions of most of the therapies approved before 2000 are currently utilized for the management of PONV.

Aloxi is an intravenous palonosetron hydrochloride injection developed by Eisai Corporation of North America, its US subsidiary MGI Pharma, and Helsinn Healthcare. In February 2008, the US FDA approved Aloxi IV injection for the prevention of PONV for up to 24 h following surgery. In phase III clinical study the most frequently observed side effects with Aloxi were electrocardiogram (ECG) QT prolongation (five percent), bradycardia (four percent), headache (three percent), and constipation (two percent) (Eisai Corporation, 2008).

Zuplenz is an oral soluble film containing ondansetron in 4 mg and 8 mg strength. In July 2011, it was approved in the US for the prevention of PONV. The patents of Aloxi and Zuplenz will expire in 2024 and 2030, respectively.

Post-Operative Nausea and Vomiting (PONV) Market Outlook

The market size of PONV in the seven major markets (7MM) was USD 1,890.53 million in 2017. In addition, the Prophylactic and Rescue treatment market size of PONV in the seven major markets (7MM) was USD 1,272.81 million and USD 617.72 million in 2017.

Post-Operative Nausea and Vomiting (PONV) Drugs Uptake

There are only a few companies that are working for the management of PONV, and that includes Acacia Pharma (Barhemsys), Cara Therapeutics (CR845), Braeburn Pharmaceuticals, and Camurus.

Barhemsys (formerly known as APD421 and Baremsis) is an intravenous formulation of amisulpride, a selective small-molecule dopamine antagonist, which has completed phase III clinical development for the prophylaxis and treatment of PONV, alone and in combination with other antiemetic.

CR845 (also known as difelikefalin) which is under development by Cara is an analgesic opioid peptide acting as a peripherally specific, highly selective agonist of the kappa opioid receptor. It is currently investigated in phase II/III clinical study for the management of PONV.

PONV Report Insights

  • Patient Population by total Inpatient Surgical cases
  • Total PONV cases
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

PONV Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

PONV Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the PONV market
  • Organize sales and marketing efforts by identifying the best opportunities for PONV market
  • To understand the future market competition in the PONV market.

Table of Contents

1. Key Insights

2. PONV Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Postoperative Nausea and Vomiting (PONV) in 2017
  • 2.2. Market Share (%) Distribution of Postoperative Nausea and Vomiting (PONV) in 2028

3. Postoperative Nausea and Vomiting (PONV): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Etiology and Risk Factors of Postoperative Nausea and Vomiting (PONV)
  • 3.3. Causes of PONV
    • 3.3.1. Complications of PONV specific to surgery and anesthesia
  • 3.4. Pathophysiological and neurochemical mechanisms of Postoperative Nausea and Vomiting (PONV)
    • 3.4.1. Clinical evidence for the role of volatile anesthetics and opioids
    • 3.4.2. Neural systems for emetic action
  • 3.5. Genetic background of Postoperative Nausea and Vomiting (PONV)
  • 3.6. Risk scores for predicting Postoperative Nausea and Vomiting (PONV)

4. Case Reports

  • 4.1. Case report: Post-operative nausea and vomiting
  • 4.2. Postoperative Complications

5. Epidemiology and Patient Population

  • 5.1. Key Findings
  • 5.2. Epidemiology and Market Methodology
  • 5.3. Total Inpatients Surgeries in the 7MM
  • 5.4. Total Postoperative Nausea and Vomiting (PONV) Cases in the 7MM
  • 5.5. United States Epidemiology
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Total Inpatient Surgery Cases in the United States
    • 5.5.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in the United States
    • 5.5.4. Total Number of Post-Operative Nausea and Vomiting patients in the United States
  • 5.6. EU5 Epidemiology
    • 5.6.1. Germany
      • 5.6.1.1. Assumptions and Rationale
      • 5.6.1.2. Total Inpatient Surgery Cases in Germany
      • 5.6.1.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Germany
      • 5.6.1.4. Total Number of Post-Operative Nausea and Vomiting patients in Germany
    • 5.6.2. France
      • 5.6.2.1. Assumptions and Rationale
      • 5.6.2.2. Total Inpatient Surgery Cases in France
      • 5.6.2.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in France
      • 5.6.2.4. Total Number of Post-Operative Nausea and Vomiting patients in France
    • 5.6.3. Italy
      • 5.6.3.1. Assumptions and Rationale
      • 5.6.3.2. Total Inpatient Surgery Cases in Italy
      • 5.6.3.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Italy
      • 5.6.3.4. Total Number of Post-Operative Nausea and Vomiting patients in Italy
    • 5.6.4. Spain
      • 5.6.4.1. Assumptions and Rationale
      • 5.6.4.2. Total Inpatient Surgery Cases in Spain
      • 5.6.4.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Spain
      • 5.6.4.4. Total Number of Post-Operative Nausea and Vomiting patients in Spain
    • 5.6.5. United Kingdom
      • 5.6.5.1. Assumptions and Rationale
      • 5.6.5.2. Total Inpatient Surgery Cases in the UK
      • 5.6.5.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in the UK
      • 5.6.5.4. Total Number of Post-Operative Nausea and Vomiting patients in the UK
  • 5.7. Japan Epidemiology
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Total Inpatient Surgery Cases in Japan
    • 5.7.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Japan
    • 5.7.4. Total Number of Post-Operative Nausea and Vomiting patients in Japan

6. Treatment and Management of Postoperative Nausea and Vomiting (PONV)

  • 6.1. First-line antiemetic interventions
  • 6.2. Second-line antiemetic interventions
  • 6.3. Preventive and therapeutic strategies
  • 6.4. Treatment Algorithm
  • 6.5. Treatment Guidelines
    • 6.5.1. ASPAN'S Evidence-Based Clinical Practice Guideline for the Prevention and/or Management of PONV/PDNV
    • 6.5.2. French Society of Anesthesia and Resuscitation Guidelines for Management of PONV

7. Unmet Needs

8. Marketed Drugs

  • 8.1. Aloxi (palonosetron hydrochloride): Helsinn Healthcare
    • 8.1.1. Drug Description
    • 8.1.2. Regulatory Milestones
    • 8.1.3. Other Development Activities
    • 8.1.4. Advantages and Disadvantages
    • 8.1.5. Safety and Efficacy
    • 8.1.6. Product Profile
  • 8.2. Zuplenz (ondansetron): Midatech/Galena Biopharma
    • 8.2.1. Drug Description
    • 8.2.2. Regulatory Milestones
    • 8.2.3. Other Development Activities
    • 8.2.4. Advantages and Disadvantages
    • 8.2.5. Safety and Efficacy
    • 8.2.6. Product Profile
  • 8.3. Emend (aprepitant): Merck
    • 8.3.1. Drug Description
    • 8.3.2. Regulatory Milestones
    • 8.3.3. Other Development Activities
    • 8.3.4. Advantages and Disadvantages
    • 8.3.5. Safety and Efficacy
    • 8.3.6. Product Profile

9. Emerging Drugs

  • 9.1. Barhemsys (APD421): Acacia Pharma
    • 9.1.1. Product Description
    • 9.1.2. Other Developmental Activities
    • 9.1.3. Clinical Development
    • 9.1.4. Clinical trial information
    • 9.1.5. Safety and Efficacy
    • 9.1.6. Product Profile
  • 9.2. CR845 (difelikefalin): Cara Therapeutics
    • 9.2.1. Product Description
    • 9.2.2. Other Developmental Activities:
    • 9.2.3. Clinical Development
    • 9.2.4. Clinical trial information
    • 9.2.5. Safety and Efficacy
    • 9.2.6. Product Profile
  • 9.3. CAM2058: Camurus/Braeburn
    • 9.3.1. Product Description
    • 9.3.2. Other Developmental Activities
    • 9.3.3. Clinical Development
    • 9.3.4. Clinical trial information
    • 9.3.5. Safety and Efficacy
    • 9.3.6. Product Profile

10. Postoperative Nausea and Vomiting (PONV): 7 Major Market Analysis

  • 10.1. Key Findings
  • 10.2. Total Market Size of Postoperative Nausea and Vomiting (PONV) in the 7MM
  • 10.3. PONV Prophylactic Market by Current and Emerging Therapies
  • 10.4. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies.
  • 10.5. Market Size of Postoperative Nausea and Vomiting (PONV) by Therapies in the 7MM

11. Market Outlook: 7MM

  • 11.1. United States Market Size
    • 11.1.1. The total Market size of Postoperative Nausea and Vomiting (PONV)
    • 11.1.2. PONV Prophylactic Market by Current and Emerging Therapies
    • 11.1.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies
    • 11.1.4. Total PONV Market Size by Therapies
  • 11.2. EU5
    • 11.2.1. Germany
      • 11.2.1.1. The total Market size of Postoperative Nausea and Vomiting (PONV)
      • 11.2.1.2. PONV Prophylactic Market by Current and Emerging Therapies
      • 11.2.1.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies
      • 11.2.1.4. Total PONV Market Size by Therapies
    • 11.2.2. France
      • 11.2.2.1. The total Market size of Postoperative Nausea and Vomiting (PONV)
      • 11.2.2.2. PONV Prophylactic Market by Current and Emerging Therapies
      • 11.2.2.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies
      • 11.2.2.4. Total PONV Market Size by Therapies
    • 11.2.3. Italy
      • 11.2.3.1. The total Market size of Postoperative Nausea and Vomiting (PONV)
      • 11.2.3.2. PONV Prophylactic Market by Current and Emerging Therapies
      • 11.2.3.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies
      • 11.2.3.4. Total PONV Market Size by Therapies
    • 11.2.4. Spain
      • 11.2.4.1. The total Market size of Postoperative Nausea and Vomiting (PONV)
      • 11.2.4.2. PONV Prophylactic Market by Current and Emerging Therapies
      • 11.2.4.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies
      • 11.2.4.4. Total PONV Market Size by Therapies
    • 11.2.5. United Kingdom
      • 11.2.5.1. The total Market size of Postoperative Nausea and Vomiting (PONV)
      • 11.2.5.2. PONV Prophylactic Market by Current and Emerging Therapies
      • 11.2.5.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies
      • 11.2.5.4. Total PONV Market Size by Therapies
  • 11.3. Japan
    • 11.3.1. The total Market size of Postoperative Nausea and Vomiting (PONV)
    • 11.3.2. PONV Prophylactic Market by Current and Emerging Therapies
    • 11.3.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies
    • 11.3.4. Total PONV Market Size by Therapies

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix

  • 15.1. Bibliography
  • 15.2. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

List of Tables

Table 1 Candidate genes that affect nausea and vomiting

Table 2 Total Inpatient Surgeries in the 7MM (2017-2028)

Table 3 Total Postoperative Nausea and Vomiting (PONV) Cases in the 7MM (2017-2028)

Table 4 Total Inpatient Surgery Cases in the United States (2017-2028)

Table 5 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in the United States (2017-2028)

Table 6 Total Number of Post-Operative Nausea and Vomiting patients in the United States (2017-2028)

Table 7 Total Inpatient Surgery Cases in Germany (2017-2028)

Table 8 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Germany (2017-2028)

Table 9 Total Number of Post-Operative Nausea and Vomiting patients in Germany (2017-2028)

Table 10 Total Inpatient Surgery Cases in France (2017-2028)

Table 11 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in France (2017-2028)

Table 12 Total Number of Post-Operative Nausea and Vomiting patients in France (2017-2028)

Table 13 Total Inpatient Surgery Cases in Italy (2017-2028)

Table 14 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Italy (2017-2028)

Table 15 Total Number of Post-Operative Nausea and Vomiting patients in Italy (2017-2028)

Table 16 Total Inpatient Surgery Cases in Spain (2017-2028)

Table 17 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Spain (2017-2028)

Table 18 Total Number of Post-Operative Nausea and Vomiting patients in Spain (2017-2028)

Table 19 Total Inpatient Surgery Cases in the UK (2017-2028)

Table 20 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in the UK (2017-2028)

Table 21 Total Number of Post-Operative Nausea and Vomiting patients in the UK (2017-2028)

Table 22 Total Inpatient Surgery Cases in Japan (2017-2028)

Table 23 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Japan (2017-2028)

Table 24 Total Number of Post-Operative Nausea and Vomiting patients in Japan (2017-2028)

Table 25 Advantages and side effects of different classes of antiemetic

Table 26 Recommended dosages of antiemetic drugs for prophylaxis in adult patients

Table 27 Pharmacologic combination therapy for adults and children

Table 28 Antiemetic doses for prophylaxis of POV in children

Table 29 Antiemetic Doses and Timing for Prevention of Postoperative Nausea and Vomiting in Adult

Table 30 Recommendations by the French Society of Anesthesia and Resuscitation

Table 31 Barhemsys patents

Table 32 Barhemsys, Clinical Trial Description, 2019

Table 33 CR845, Clinical Trial Description, 2019

Table 34 CAM2058, Clinical Trial Description, 2019

Table 35 Market size of PONV by Region in USD Million (2017-2028)

Table 36 7MM Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Table 37 7MM Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Table 38 7MM Size of PONV by Therapies in USD Million (2017-2028)

Table 39 United States Market Size of PONV in USD Million (2017-2028)

Table 40 The US Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Table 41 The US Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Table 42 The US Market Size of PONV by Therapies in USD Million (2017-2028)

Table 43 Germany Market Size of PONV in USD Million (2017-2028)

Table 44 Germany Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Table 45 Germany Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Table 46 Germany Market Size of PONV by Therapies in USD Million (2017-2028)

Table 47 France Market Size of PONV in USD Million (2017-2028)

Table 48 France Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Table 49 France Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Table 50 France Market Size of PONV by Therapies in USD Million (2017-2028)

Table 51 Italy Market Size of PONV in USD Million (2017-2028)

Table 52 Italy Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Table 53 Italy Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Table 54 Italy Market Size of PONV by Therapies in USD Million (2017-2028)

Table 55 Spain Market Size of PONV in USD Million (2017-2028)

Table 56 Spain Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Table 57 Spain Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Table 58 Spain Market Size of PONV by Therapies in USD Million (2017-2028)

Table 59 United Kingdom Market Size of PONV in USD Million (2017-2028)

Table 60 UK Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Table 61 UK Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Table 62 UK Market Size of PONV by Therapies in USD Million (2017-2028)

Table 63 Japan Market Size of PONV in USD Million (2017-2028)

Table 64 Japan Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Table 65 Japan Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Table 66 Japan Market Size of PONV by Therapies in USD Million (2017-2028)

List of Figures

Figure 1 Causes of vomiting

Figure 2 Risk factors associated with PONV

Figure 3 Neural pathways and pharmacology of PONV

Figure 4 Total Inpatient Surgeries in the 7MM (2017-2028)

Figure 5 Total Postoperative Nausea and Vomiting (PONV) Cases in the 7MM (2017-2028)

Figure 6 Total Inpatient Surgery Cases in the United States (2017-2028)

Figure 7 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in the United States (2017-2028)

Figure 8 Total Number of Post-Operative Nausea and Vomiting patients in the United States (2017-2028)

Figure 9 Total Inpatient Surgery Cases in Germany (2017-2028)

Figure 10 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Germany (2017-2028)

Figure 11 Total Number of Post-Operative Nausea and Vomiting patients in Germany (2017-2028)

Figure 12 Total Inpatient Surgery Cases in France (2017-2028)

Figure 13 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in France (2017-2028)

Figure 14 Total Number of Post-Operative Nausea and Vomiting patients in France (2017-2028)

Figure 15 Total Inpatient Surgery Cases in Italy (2017-2028)

Figure 16 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Italy (2017-2028)

Figure 17 Total Number of Post-Operative Nausea and Vomiting patients in Italy (2017-2028)

Figure 18 Total Inpatient Surgery Cases in Spain (2017-2028)

Figure 19 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Spain (2017-2028)

Figure 20 Total Number of Post-Operative Nausea and Vomiting patients in Spain (2017-2028)

Figure 21 Total Inpatient Surgery Cases in the UK (2017-2028)

Figure 22 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in the UK (2017-2028)

Figure 23 Total Number of Post-Operative Nausea and Vomiting patients in the UK (2017-2028)

Figure 24 Total Inpatient Surgery Cases in Japan (2017-2028)

Figure 25 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Japan (2017-2028)

Figure 26 Total Number of Post-Operative Nausea and Vomiting patients in Japan (2017-2028)

Figure 27 Algorithm for the management of PONV

Figure 28 Algorithm for PONV prophylaxis

Figure 29 Algorithm for PONV prophylaxis

Figure 30 Unmet needs of PONV

Figure 31 Market size of PONV by Region in USD Million (2017-2028)

Figure 32 7MM Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Figure 33 7MM Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Figure 34 Market Size of PONV by Therapies in the 7MM, in USD Million (2017-2028)

Figure 35 United States Market Size of PONV in USD Million (2017-2028)

Figure 36 The US Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Figure 37 The US Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Figure 38 The US Market Size of PONV by Therapies in USD Million (2017-2028)

Figure 39 Germany Market Size of PONV in USD Million (2017-2028)

Figure 40 Germany Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Figure 41 Germany Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Figure 42 Germany Market Size of PONV by Therapies in USD Million (2017-2028)

Figure 43 France Market Size of PONV in USD Million (2017-2028)

Figure 44 France Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Figure 45 France Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Figure 46 France Market Size of PONV by Therapies in USD Million (2017-2028)

Figure 47 Italy Market Size of PONV in USD Million (2017-2028)

Figure 48 Italy Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Figure 49 Italy Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Figure 50 Italy Market Size of PONV by Therapies in USD Million (2017-2028)

Figure 51 Spain Market Size of PONV in USD Million (2017-2028)

Figure 52 Spain Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Figure 53 Spain Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Figure 54 Spain Market Size of PONV by Therapies in USD Million (2017-2028)

Figure 55 United Kingdom Market Size of PONV in USD Million (2017-2028)

Figure 56 UK Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Figure 57 UK Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Figure 58 UK Market Size of PONV by Therapies in USD Million (2017-2028)

Figure 59 Japan Market Size of PONV in USD Million (2017-2028)

Figure 60 Japan Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028)

Figure 61 Japan Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028)

Figure 62 Japan Market Size of PONV by Therapies in USD Million (2017-2028)

Figure 63 Market Drivers

Figure 64 Market Barriers

Figure 65 SWOT analysis